CARA earnings call for the period ending September 30, 2019.
Investing.com - These stocks were active postmarket. - Clean Energy Fuels (NASDAQ:CLNE) shares moved up 5% after the company reported a loss of 1 cent a share, better than the...
Based on an interim analysis by the independent Data Monitoring Committee, the Phase 3 clinical trial, KALM-1, evaluating Cara Therapeutics' (NASDAQ:CARA) KORSUVA (difelikefalin)...
Investors in Cara Therapeutics, Inc. (NASDAQ:CARA) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2019 $20.00...
AquaBounty Technologies, Inc. (AQB) AQB popped 45 cents on Monday, or 13%, to 3.93, on 470,362 shares traded and took out resistance at the level where it exploded in March. If it...
Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) increased about 20% after the company announced positive top-line data from the KALM-1 pivotal phase III study of Korsuva...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Sell||Buy||Strong Buy|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Buy||Strong Buy|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Doji Star Bearish||1W||1||Nov 03, 2019|
|Homing Pigeon||15||1||Nov 15, 2019 03:30PM|
|Deliberation Bearish||1D||4||Nov 11, 2019|
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.Read More
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.